The People of OyaGen
Richard V. McCloskey, M.S., M.D., Preclinical Advisor
Dr. McCloskey graduated from The University of Rochester Medical School with an M.D. with honors and an M.S. in Microbiology. Post graduate training was at Duke University Medical Center and the National Institutes of Health. He was a founding faculty member of the University of Texas Medical School at San Antonio. He is certified by the American Boards of Internal Medicine and Infectious Diseases, and is an emeritus member of the Infectious Diseases Society of America. Clinical appointments have been as Chair of Medicine at Albert Einstein Medical Center, Daroff Division, and Chief of Infectious Diseases at Presbyterian-University of Pennsylvania Medical Center, both in Philadelphia. Dr. McCloskey was also Vice President of Clinical Research at Centocor and Vice President of Medical Technology at Johnson and Johnson Development Corporation until 2008. He currently is Scientific Adviser for Endo Pharmaceuticals and a consultant to the Corporate Office of Science and Technology of Johnson and Johnson.
The following drugs were approved either in USA , Europe or Japan. Dr. McCloskey contributed to the following as a pharmaceutical R&D director: interferon, midazolam, ceftriaxone, HA1A, abciximab and infliximab.
Dr.McCloskey contributed to the following as an academic clinical investigator: cefoxitin, thienamycin, cefotaxime, mezlocillin, ticarcillin, imipenem-cilastatin, cefmenoxime, amdinocillin, fleroxacin and ofloxacin.